Non-steroidal anti-inflammatory drugs and cardiovascular risk : a rheumatologist's reply

dc.contributor.author	Whitelaw, David
dc.date.accessioned	2011-03-18T14:59:23Z
dc.date.available	2011-03-18T14:59:23Z
dc.date.issued	2007-12
dc.description	Letter
dc.description	The original publication is available at http://www.samj.org.za
dc.description.abstract	To the Editor: The cyclo-oxygenase-2 (COX-2) inhibitors and other non-steroidal anti-inflammatory drugs (NSAIDs) have been the subject of scrutiny generated mainly by evidence suggesting that rofecoxib is associated with increased cardiovascular risk. Chin and Commerford1 have summarised some of the large volume of data; however, a critical review of published work yields interesting insights.
dc.description.version	Publishers' Version
dc.format.extent	p. 1230
dc.identifier.citation	Whitelaw, D. 2007. Non-steroidal anti-inflammatory drugs and cardiovascular risk - a rheumatologist's reply. South African Medical Journal, 97(12):1230.
dc.identifier.issn	2078-5135 (online)
dc.identifier.issn	0256-9574 (print)
dc.identifier.uri	http://hdl.handle.net/10019.1/7803
dc.language.iso	en_ZA
dc.publisher	Health and Medical Publishing Group (HMPG)
dc.rights.holder	SAMJ reserves copyright of the material published
dc.subject	Nonsteroidal anti-inflammatory agents	en_ZA
dc.subject	Cardiovascular system -- Diseases	en_ZA
dc.title	Non-steroidal anti-inflammatory drugs and cardiovascular risk : a rheumatologist's reply	en_ZA
dc.type	Letter

Now showing 1 - 1 of 1